1.A Case of Concurrent Esophageal and Doudenal Double Primary Cancer.
Chai Ho LIM ; Hai Ju YANG ; Young Wan KIM ; Wan Jae HEO ; Jae Sun KIM ; Nag Hyun SEONG ; Koung Sik PARK ; Jong Beom CHOI ; Seok In JEONG
Korean Journal of Gastrointestinal Endoscopy 1997;17(4):533-538
The occurrence of double primary cancer of the esopbagus and duodenum is considered very rare. Moreover, it is difficult to manage this type of double cancer because esophageal cancer has a biologic tendency to early metastasis. We report a case of double primary cancer, which we have synchronously confirmed esophageal squamous cell carcinoma and duodenal adenocarcinoma with gastrofiberscopic biopsy, and then treated them by gastrojejunostomy and systemic chemotherapy.
Adenocarcinoma
;
Biopsy
;
Carcinoma, Squamous Cell
;
Drug Therapy
;
Duodenum
;
Esophageal Neoplasms
;
Gastric Bypass
;
Neoplasm Metastasis
2.Clinical characteristics of digestive system cancers metastatic to the heart.
Jia Lin TANG ; Bo ZHANG ; Xing Yuan WANG ; Yan SONG ; Jian Ping XU ; Tao QU ; Yihebali CHI ; Jing HUANG
Chinese Journal of Oncology 2022;44(11):1229-1232
Objective: To investigate the clinical features of patients with cardiac metastases from digestive system tumors. Methods: This retrospective study collected and analyzed the medical records of patients with cardiac metastases from digestive system tumors who received treatments in the Cancer Hospital, Chinese Academy of Medical Sciences between January 1999 and January 2021. Kaplan-Meier method was used for survival analysis. Results: A total of 19 patients were identified. The primary tumors were esophageal squamous cell carcinoma (n=7), gastric or gastroesophageal junction adenocarcinoma (n=6), hepatobiliary cancers (n=3) and colorectal cancers (n=3). 16 patients had pericardial metastases, 2 patients had right atrium metastases, and 1 patient had left ventricle metastasis. The most common symptom was dyspnea, which was present in 8 cases. 7 patients received locoregional treatment, while 11 patients underwent systemic therapies. The median overall survival from diagnosis of primary cancer was 31.4 months, and the median overall survival time from diagnosis of cardiac metastasis was 4.7 months. Conclusion: Cardiac metastasis from digestive system tumors is associated with low incidence and a poor prognosis. Systemic treatment remains the cornerstone of management, while novel anti-tumor drugs may improve therapeutic efficacy.
Humans
;
Esophageal Neoplasms/pathology*
;
Retrospective Studies
;
Prognosis
;
Esophageal Squamous Cell Carcinoma
;
Digestive System Neoplasms/drug therapy*
;
Gastrointestinal Neoplasms
3.Repurposed benzydamine targeting CDK2 suppresses the growth of esophageal squamous cell carcinoma.
Yubing ZHOU ; Xinyu HE ; Yanan JIANG ; Zitong WANG ; Yin YU ; Wenjie WU ; Chenyang ZHANG ; Jincheng LI ; Yaping GUO ; Xinhuan CHEN ; Zhicai LIU ; Jimin ZHAO ; Kangdong LIU ; Zigang DONG
Frontiers of Medicine 2023;17(2):290-303
Esophageal squamous cell carcinoma (ESCC) is one of the leading causes of cancer death worldwide. It is urgent to develop new drugs to improve the prognosis of ESCC patients. Here, we found benzydamine, a locally acting non-steroidal anti-inflammatory drug, had potent cytotoxic effect on ESCC cells. Benzydamine could suppress ESCC proliferation in vivo and in vitro. In terms of mechanism, CDK2 was identified as a target of benzydamine by molecular docking, pull-down assay and in vitro kinase assay. Specifically, benzydamine inhibited the growth of ESCC cells by inhibiting CDK2 activity and affecting downstream phosphorylation of MCM2, c-Myc and Rb, resulting in cell cycle arrest. Our study illustrates that benzydamine inhibits the growth of ESCC cells by downregulating the CDK2 pathway.
Humans
;
Benzydamine
;
Esophageal Neoplasms/drug therapy*
;
Esophageal Squamous Cell Carcinoma/drug therapy*
;
Molecular Docking Simulation
;
Phosphorylation
;
Cell Proliferation
;
Cell Line, Tumor
;
Apoptosis
;
Cyclin-Dependent Kinase 2
4.Efficacy and safety of neoadjuvant chemotherapy combined with PD-1 antibody for esophageal squamous cell carcinoma in the real world.
Pu Yuan WU ; Tao WANG ; Bao Jun CHEN ; Min Ke SHI ; Bin HUANG ; Nan Die WU ; Liang QI ; Xiao Feng CHANG ; Li Feng WANG ; Bao Rui LIU ; Wei REN
Chinese Journal of Oncology 2023;45(2):170-174
Objective: To evaluate the efficacy and safety of neoadjuvant chemotherapy combined with programmed death-1 (PD-1) antibody in operable, borderline or potentially resectable locally advanced esophageal squamous cell carcinoma(ESCC) in the real world. Methods: The study retrospectively analyzed 28 patients with operable or potentially resectable locally advanced ESCC patients treated with preoperative chemotherapy combined with PD-1 inhibitor in Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School from April 2020 to March 2021. According to the clinical TNM staging system of the 8th edition of the American Joint Committee on Cancer, there were 1, 15, 10, 1 and 1 case of stage Ⅱ, Ⅲ, ⅣA, ⅣB and unknown stage respectively. The treatment was two cycle of dual drug chemotherapy regimen including taxane plus platinum or fluorouracil combined with PD-1 antibody followed by tumor response assessment and surgery if the patient was eligible for resection. Results: Of the 28 patients, 1, 2, 3 and 4 cycles of chemotherapy combined with PD-1 antibody treatment completed in 1, 21, 5, and 1 patient, respectively. Objective response rate (ORR) was 71.4% (20/28), and disease control rate (DCR) was 100% (28/28). The incidence of adverse events exceeding grade 3 levels was 21.4% (6/28), including 3 neutropenia, 1 leukopenia, 1 thrombocytopenia and 1 immune hepatitis. There was no treatment-related death. Of the 23 patients underwent surgery, R0 resection rate was 87.0% (20/23), 13 patients had down staged to the T1-2N0M0 I stage, the pCR rate was 17.3% (4/23), and the pCR rate of primary tumor was 21.7% (5/23). Four patients received definitive chemoradiotherapy. One patient rejected surgery and other treatment after achieved PR response. Conclusion: Neoadjuvant chemotherapy combined PD-1 inhibitor is safe and has high efficacy in operable, borderline or potentially resectable locally advanced ESCC, and it is a promising regimen.
Humans
;
Antibodies/therapeutic use*
;
Antineoplastic Combined Chemotherapy Protocols
;
Carcinoma, Squamous Cell/surgery*
;
Cisplatin
;
Esophageal Neoplasms/surgery*
;
Esophageal Squamous Cell Carcinoma/drug therapy*
;
Immune Checkpoint Inhibitors/therapeutic use*
;
Neoadjuvant Therapy
;
Programmed Cell Death 1 Receptor/therapeutic use*
;
Retrospective Studies
;
Treatment Outcome
5.A Case of Concurrent Esophageal and Gastric Double Primary Cancer Treated by Surgery and Chemotherapy.
Young Soo KIM ; Yong Woon SHIN ; Won Jae CHUNG ; Seok JEONG ; Kye Sook KWON ; Jin Woo LEE ; Gi Soo PARK ; Dong Seob JANG ; Sun Hoo KIM ; Yeo Joo KIM ; Seong Bin HONG
Korean Journal of Gastrointestinal Endoscopy 1995;15(4):721-727
Double primary cancer of the stomach and esophagus has been revealed a very low incidence in the world except Japan and reported only 6 cases in Korea. Furthermore, it is difficult to manage this type of double cancer because esophageal cancer has a biologic tendency to early metastasis. This paper is concerned with a case of double primary cancer, which we have synchroniously confi~rmed esophageal squamous cell carcinoma and gastric adenocarcinoma with gastrofiberscopic biopsy, and then treated them by radical resec tion and systemic chemotherapy.
Adenocarcinoma
;
Biopsy
;
Carcinoma, Squamous Cell
;
Drug Therapy*
;
Esophageal Neoplasms
;
Esophagus
;
Incidence
;
Japan
;
Korea
;
Neoplasm Metastasis
;
Stomach Neoplasms
6.Results of Radiotherapy With and Without Chemotherapy for Esophageal Cancers.
Sang Bo KIM ; Sangs Mo YUN ; Samuel RYU ; In Kyu PARK
Journal of the Korean Society for Therapeutic Radiology 1991;9(2):233-239
This is a retrospective study of 62 patients with unresected squamous cell carcinoma of the esophagus treated by radiotherapy alone (25 patients) or combined chemotherapy and radiotherapy (37 patients). Of these, 14 of 25 patients treated by radiation therapy alone and 25 of 37 patients treated by combined chemotherapy and radiotherapy completed radiotherapy consisting of 55 to 60 Gy in 5 to 6 weeks and were analyzed for local control rate and survival rate. Follow up ranged from 6 days to 58 months. Three (8%) of 39 patients had a complete response, twenty-eight(72%) a partial reponse and eight(20%) minimal or no resonse. Overall median survival was 11 months for all stages. The 1 year and 2 year actuarial survival rates were 48.6% and 13% respectively. Age and stage had prognostic significances (p<0.05, p<0.05 respectively). The 1 year survival rate was 70.1% for stage I, 47.6% for stage II, and 28.4% for stage III. The median survival was 19 months for stage I, 11 months for stage II, 6 months for stage III, and 5.5 months for stage III with distant metastases. The 1 year survival rate of patients 55 years and above was 69.6%, 54 years and below was 0%. There was no significant difference in survival rate between treatment modalities, locations of tumor, and responses of tumor.
Carcinoma, Squamous Cell
;
Drug Therapy*
;
Esophageal Neoplasms*
;
Esophagus
;
Follow-Up Studies
;
Humans
;
Neoplasm Metastasis
;
Radiotherapy*
;
Retrospective Studies
;
Survival Rate
7.Treatment Results of Esophageal Carcinoma Treated by Radiation Therapy.
Mi Sook KIM ; Seoung Yul YOO ; Chul Koo CHO ; Hyung Jun YOO ; Kwang Mo YANG ; Jin Oh KANG ; Young Hoo JI ; Dong Hoon LEE ; Baek Yeol RYOO
The Journal of the Korean Society for Therapeutic Radiology and Oncology 2000;18(3):182-186
PURPOSE: To determine treatment protocol for inoperable esophageal cancer patients, we evaluated survival rate and prognostic factors. MATERIALS AND METHODS: We evaluated esophageal cancer treated by curative or palliative aim in KCCH from 1992 to 1996, retrospectively. Recurrent or underdose case below 40 Gy were excluded. The number of male and female were 35 and 5, respectively. Thirty-eight patients were squamous carcinoma and 2 patients were not biopsy proven. Ten patients were treated with radiation therapy and chemotherapy. Median dose of radiation therapy was 59.4 Gy and the range was 40-60 Gy. RESULTS:The median survival is 6.5 months and 1-year survival rate was 28.3%. Age, location, radiation dose and chemotherapy were not significant prognostic factors. Median survivals of patients with below stage III and over stage IVA were 7.6 and 6.2 months respectively, but it is not significant. CONCLUSION:The survival for esophageal cancer is very poor. For patients with curative aim, chemotherapy must be considered. For patients with palliative aim, short-term external beam radiation therapy and/or brachytherapy must be considered.
Biopsy
;
Brachytherapy
;
Carcinoma, Squamous Cell
;
Clinical Protocols
;
Drug Therapy
;
Esophageal Neoplasms
;
Female
;
Humans
;
Male
;
Retrospective Studies
;
Survival Rate
8.MDM2, p53 and pRb Expression Prior to Definitive Chemoradiotherapy in Esophageal Carcinoma.
Mee Sun YOON ; Taek Keun NAM ; Jae Hyuk LEE ; Sang Hee CHO ; Ju Young SONG ; Sung Ja AHN ; Ik Joo CHUNG ; Woong Ki CHUNG ; Byung Sik NAH
The Journal of the Korean Society for Therapeutic Radiology and Oncology 2007;25(4):193-200
PURPOSE: This study evaluated the pretreatment expression patterns of MDM2, p53, and pRb proteins to determine if the expression patterns could predict the outcome of concurrent chemoradiotherapy (CCRT) for esophageal squamous cell carcinoma and aid in the decisions for the selection of treatment modalities. MATERIALS AND METHODS: Fifty-one patients that were treated with definitive chemoradiotherapy for stage I~IVa esophageal squamous cell carcinoma were selected for this study. Radiotherapy was administered with daily 1.8~2 Gy fractions up to a median dose of 54 Gy for primary tumors, and with four cycles of cisplatin/5- fluorouracil chemotherapy that was administered every 4 weeks, the first two cycles of which were administered concurrently with radiotherapy. Expression of MDM2, p53, and pRb was investigated by immunohistochemical analysis using pretreatment biopsy specimens. RESULTS: MDM2, p53, and pRb were detected with high immunoreactivity in 19.6%, 27.5%, and 66.7% of the patients, respectively. However, there was no significant correlation between expression of these factors and clinical outcome. By the use of multivariate analysis with nine covariates-age, tumor location, tumor length, stage, pathological response, clinical response, MDM2 expression, p53 expression, and pRb expression, only pathological response and stage were significant factors for cause-specific survival. CONCLUSION: Expression of MDM2, p53, and pRb was not found to be clinically significant for predicting outcomes after CCRT in this study. Further studies with a larger patient population and longer follow-up periods are needed to re-evaluate the expression pattern and to identify new predictors for CCRT response.
Biopsy
;
Carcinoma, Squamous Cell
;
Chemoradiotherapy*
;
Drug Therapy
;
Esophageal Neoplasms
;
Fluorouracil
;
Follow-Up Studies
;
Humans
;
Immunohistochemistry
;
Multivariate Analysis
;
Radiotherapy
9.Therapeutic effect of combined cisplatin and docetaxel vs fluorouracil regimen with concurrent radiotherapy on advanced esophageal carcinoma.
Si-Ze CHEN ; Xue-Mei CHEN ; Ying DING ; Xi-Cheng WANG ; Fan ZHANG ; Kai-Lan MO
Journal of Southern Medical University 2011;31(4):727-729
OBJECTIVETo compare the therapeutic effect and adverse effects of two regimens, namely cisplatin and docetaxel (DC) regimen and fluorouracil (PF) regimen, both with concurrent radiotherapy, in the treatment of advanced esophageal squamous cancer.
METHODSForty-eight patients with esophageal squamous cancer were randomly assigned in DC regimen and PF regimen groups. All the patients received conventional radiotherapy at a total dose of 60 Gy (in 30 fractions) for 6 weeks. In DC regimen group, the patients received intravenous infusion of docetaxel (75 mg/m(2)) for 1 h on day 1 and DDP (25 mg/m(2) daily) on days 1-3, with every 28 days as one cycle. PF regimen consisted of cisplatin (25 mg/m(2)) on days 1-3 and continuous intravenous infusion of fluorouracil (500 mg/m(2)) for 5 days, with every 28 days as one cycle. All the patients were suggested to have no less than 2 cycles.
RESULTSThe 3-year median survival time in DC regimen was slightly longer than that in PF regimen group (26 vs 23 months, Χ2=3.4041, P=0.065). The same result was also found in the short-term effect and adverse reactions including ?myelosuppression and gastrointestinal reactions. Only the adverse reaction of radiotherapy-induced esophagitis showed a significant difference between the two groups (P=0.049).
CONCLUSIONDC regimen with synchronous radiotherapy is effective and safe for treating advanced esophageal squamous cancer.
Adult ; Aged ; Antineoplastic Protocols ; Carcinoma, Squamous Cell ; drug therapy ; radiotherapy ; therapy ; Combined Modality Therapy ; Esophageal Neoplasms ; drug therapy ; radiotherapy ; therapy ; Female ; Humans ; Male ; Middle Aged
10.Clinical analysis of liver dysfunction induced by SHR-1210 alone or combined with apatinib and chemotherapy in patients with advanced esophageal squamous cell carcinoma.
Ling QI ; Bo ZHANG ; Yun LIU ; Lan MU ; Qun LI ; Xi WANG ; Jian Ping XU ; Xing Yuan WANG ; Jing HUANG
Chinese Journal of Oncology 2023;45(3):259-264
Objective: To investigate the clinical characteristics of abnormal liver function in patients with advanced esophageal squamous carcinoma treated with programmed death-1 (PD-1) antibody SHR-1210 alone or in combination with apatinib and chemotherapy. Methods: Clinical data of 73 patients with esophageal squamous carcinoma from 2 prospective clinical studies conducted at the Cancer Hospital Chinese Academy of Medical Sciences from May 11, 2016, to November 19, 2019, were analyzed, and logistic regression analysis was used for the analysis of influencing factors. Results: Of the 73 patients, 35 had abnormal liver function. 13 of the 43 patients treated with PD-1 antibody monotherapy (PD-1 monotherapy group) had abnormal liver function, and the median time to first abnormal liver function was 55 days. Of the 30 patients treated with PD-1 antibody in combination with apatinib and chemotherapy (PD-1 combination group), 22 had abnormal liver function, and the median time to first abnormal liver function was 41 days. Of the 35 patients with abnormal liver function, 2 had clinical symptoms, including malaise and loss of appetite, and 1 had jaundice. 28 of the 35 patients with abnormal liver function returned to normal and 7 improved to grade 1, and none of the patients had serious life-threatening or fatal liver function abnormalities. Combination therapy was a risk factor for patients to develop abnormal liver function (P=0.007). Conclusions: Most of the liver function abnormalities that occur during treatment with PD-1 antibody SHR-1210 alone or in combination with apatinib and chemotherapy are mild, and liver function can return to normal or improve with symptomatic treatment. For patients who receive PD-1 antibody in combination with targeted therapy and chemotherapy and have a history of long-term previous smoking, alcohol consumption and hepatitis B virus infection, liver function should be monitored and actively managed in a timely manner.
Humans
;
Esophageal Squamous Cell Carcinoma/drug therapy*
;
Esophageal Neoplasms/pathology*
;
Prospective Studies
;
Programmed Cell Death 1 Receptor/therapeutic use*
;
Antineoplastic Combined Chemotherapy Protocols/adverse effects*
;
Liver Diseases/etiology*